Castle Creek Pharmaceuticals’ Phase 2 Study of Diacerein 1% Ointment (CCP-020) for EBS


The DELIVERS study is evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).

CCP-020 is an investigational topical diacerein 1% ointment being developed by Castle Creek Pharmaceuticals. It is a potentially disease-modifying therapy that may block an important inflammatory signaling pathway associated with EBS, which could strengthen epidermal tissue and support healing.

The DELIVERS study is an International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)

Researchers will compare the efficacy of diacerein 1% ointment (CCP-020) to a control ointment when applied once-daily for eight weeks in people living with EB simplex. Participants will also report outcomes including pruritus, pain, and mobility. Follow-up visits will continue for a maximum of 22 weeks. Patients who complete the study may be eligible to enroll in a separate open-label extension study, where all participants will receive diacerein 1% ointment for 2 additional treatment cycles.

The DELIVERS study has been open since June 2017, but additional research sites have been added throughout the world over the last several months. The study is currently being conducted at about 20 locations throughout the United States, Europe, Israel and Australia. The sponsor has a travel vendor in place to assist with making travel arrangements and costs for such arrangements will be covered by the study.

For more information about the DELIVERS study including a list of participating centers and their contact information, you can visit or